{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-GMIHT2L6/bd93a27e-cae5-4f7f-b7d1-d1874a42c96d/PDF","dcterms:extent":"1297 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-GMIHT2L6/a6b897b0-53a4-406d-9c8e-bf8e3a49bfcc/TEXT","dcterms:extent":"28 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-GMIHT2L6","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2022","dc:creator":["Bolčina, Lara","Kos, Janko","Pišlar, Anja"],"dc:format":[{"@xml:lang":"sl","#text":"številka:5"},{"@xml:lang":"sl","#text":"letnik:73"},{"@xml:lang":"sl","#text":"str. 403-409"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:132623619","URN:URN:NBN:SI:doc-GMIHT2L6"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"Alzheimerjeva bolezen"},{"@xml:lang":"sl","#text":"cisteinski katepsini"},{"@xml:lang":"sl","#text":"nevrodegeneracija"},{"@xml:lang":"sl","#text":"Nevrodegenerativne bolezni"},{"@xml:lang":"sl","#text":"Parkinsonova bolezen"},{"@xml:lang":"sl","#text":"vnetni odziv"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Pomen cisteinskih peptidaz pri nevrodegenerativnih boleznih| Importance of cysteine peptidases in neurodegenerative disorders|"},"dc:description":[{"@xml:lang":"sl","#text":"The nervous system represents a broad field of potential pharmacological targets suitable for the development of new compounds for the treatment of neurological and neurodegenerative diseases. To date, a lot of research has focused on the role of cysteine peptidases, which play an important role in degradation of brain peptides playing either a neuroprotective or neurodegenerative role. Activated microglia has a significant role in inflammation-related neurodegeneration. By releasing cysteine cathepsins it promotes the development of Alzheimer's and Parkinson's disease. The proteolytic activity of cysteine cathepsins can be regulated by endogenous or exogenous inhibitors. Exogenous inhibitors open up possibilities for the development of new therapeutic approaches for the treatment of neurodegenerative diseases"},{"@xml:lang":"sl","#text":"Živčni sistem predstavlja široko raziskovalno področje za razvoj novih učinkovin, primernih za zdravljenje nevroloških in nevrodegenerativnih bolezni. Pri tem imajo pomembno vlogo cisteinske peptidaze in drugi lizosomski proteini, ki s svojim delovanjem vplivajo na sintezo in razgradnjo možganskih peptidov ter tako regulirajo številne fiziološke in patološke procese v organizmu. Ključni pomen pri z vnetjem povezani nevrodegeneraciji ima aktivirana mikroglija, ki s sproščanjem cisteinskih peptidaz vpliva na razvoj Alzheimerjeve in Parkinsonove bolezni. Proteolitično aktivnost cisteinskih peptidaz lahko regulirajo endogeni ali eksogeni zaviralci; slednji odpirajo možnosti za razvoj novih terapevtskih pristopov za zdravljenje nevrodegenerativnih bolezni"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-GMIHT2L6","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-GMIHT2L6"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-GMIHT2L6/bd93a27e-cae5-4f7f-b7d1-d1874a42c96d/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-GMIHT2L6/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-GMIHT2L6"}}}}